However, inhibiting SLC26A4 significantly reversed the increased α-SMA and cell surface area induced by PE, indicating that inhibiting SLC26A4 could attenuate myocardial fibrosis and cardiac hypertrophy. This evidence concerns the gene ACTA1 and cardiac hypertrophy.